| ID Source | ID |
|---|---|
| PubMed CID | 85184 |
| CHEMBL ID | 5220089 |
| CHEBI ID | 194805 |
| SCHEMBL ID | 3906125 |
| MeSH ID | M0404952 |
| Synonym |
|---|
| KUC100220 , |
| 6-fluoro-2-methyl-quinolin-4-ol |
| BB 0222195 |
| OPREA1_074210 |
| KUC100220N |
| 6-fluoro-2-methyl-4-quinolinol |
| AP-906/42846205 |
| 6-fluoro-4-hydroxy-2-methylquinoline, 97% |
| NCGC00159982-01 |
| 6-fluoro-4-hydroxy-2-methylquinoline |
| 15912-68-2 |
| MAYBRIDGE1_000260 |
| HMS1624G01 |
| HMS542D18 |
| AKOS002258360 |
| 6-luoro-2-methyl-1h-quinolin-4-one |
| 6-fluoro-2-methylquinolin-4-ol |
| CHEBI:194805 |
| 6-fluoro-2-methyl-1h-quinolin-4-one |
| A810000 |
| AKOS009158521 |
| 6-fluoro-2-methylquinolin-4(1h)-one |
| 389635-71-6 |
| einecs 240-054-4 |
| FT-0621125 |
| SCHEMBL3906125 |
| 4-quinolinol, 6-fluoro-2-methyl- |
| 6-fluoro-2-methyl-4-quinolinol # |
| J-650152 |
| BTB 01148 |
| F0997 |
| DTXSID60166590 |
| mfcd00041442 |
| mfcd11053891 |
| AS-60915 |
| CS-0084709 |
| F19996 |
| AMY18017 |
| A873740 |
| SB67603 |
| SB67670 |
| 6-fluoranyl-2-methyl-quinolin-4-ol |
| VBW , |
| SY049833 |
| bdbm50607320 |
| CHEMBL5220089 , |
| Class | Description |
|---|---|
| quinolone | |
| organofluorine compound | An organofluorine compound is a compound containing at least one carbon-fluorine bond. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Kelch-like ECH-associated protein 1 | Homo sapiens (human) | Ki | 2,600.0000 | 0.5600 | 0.5600 | 0.5600 | AID1918093 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Kelch-like ECH-associated protein 1 | Homo sapiens (human) | Kd | 1,800.0000 | 1.0000 | 1.7667 | 2.4000 | AID1918095 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID540299 | A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis | 2010 | Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21 | Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis. |
| AID588519 | A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities | 2011 | Antiviral research, Sep, Volume: 91, Issue:3 | High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors. |
| AID1918093 | Inhibition of recombinant human His-tagged Keap1 kelch domain (321 to 609 residues) expressed in Escherichia coli BL21(DE3) cells to Cy5-Nrf2 (unknown origin) protein-protein interaction incubated for 10 to 15 mins by fluorescence polarization assay | 2022 | Journal of medicinal chemistry, 11-10, Volume: 65, Issue:21 | Development of Noncovalent Small-Molecule Keap1-Nrf2 Inhibitors by Fragment-Based Drug Discovery. |
| AID1918095 | Binding affinity to Keap1 kelch domain (unknown origin) by surface plasmon resonance assay | 2022 | Journal of medicinal chemistry, 11-10, Volume: 65, Issue:21 | Development of Noncovalent Small-Molecule Keap1-Nrf2 Inhibitors by Fragment-Based Drug Discovery. |
| AID1794808 | Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL). | 2014 | Journal of biomolecular screening, Jul, Volume: 19, Issue:6 | A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum. |
| AID1794808 | Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL). | |||
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 2 (40.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||